Cargando…
Metabolic engineering of yeasts for green and sustainable production of bioactive ginsenosides F2 and 3β,20S-Di-O-Glc-DM
Both natural ginsenoside F2 and unnatural ginsenoside 3β,20S-Di-O-Glc-DM were reported to exhibit anti-tumor activity. Traditional approaches for producing them rely on direct extraction from Panax ginseng, enzymatic catalysis or chemical synthesis, all of which result in low yield and high cost. Me...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293705/ https://www.ncbi.nlm.nih.gov/pubmed/35865098 http://dx.doi.org/10.1016/j.apsb.2022.04.012 |
_version_ | 1784749694597988352 |
---|---|
author | Jiang, Fenglin Zhou, Chen Li, Yan Deng, Haidong Gong, Ting Chen, Jingjing Chen, Tianjiao Yang, Jinling Zhu, Ping |
author_facet | Jiang, Fenglin Zhou, Chen Li, Yan Deng, Haidong Gong, Ting Chen, Jingjing Chen, Tianjiao Yang, Jinling Zhu, Ping |
author_sort | Jiang, Fenglin |
collection | PubMed |
description | Both natural ginsenoside F2 and unnatural ginsenoside 3β,20S-Di-O-Glc-DM were reported to exhibit anti-tumor activity. Traditional approaches for producing them rely on direct extraction from Panax ginseng, enzymatic catalysis or chemical synthesis, all of which result in low yield and high cost. Metabolic engineering of microbes has been recognized as a green and sustainable biotechnology to produce natural and unnatural products. Hence we engineered the complete biosynthetic pathways of F2 and 3β,20S-Di-O-Glc-DM in Saccharomyces cerevisiae via the CRISPR/Cas9 system. The titers of F2 and 3β,20S-Di-O-Glc-DM were increased from 1.2 to 21.0 mg/L and from 82.0 to 346.1 mg/L at shake flask level, respectively, by multistep metabolic engineering strategies. Additionally, pharmacological evaluation showed that both F2 and 3β,20S-Di-O-Glc-DM exhibited anti-pancreatic cancer activity and the activity of 3β,20S-Di-O-Glc-DM was even better. Furthermore, the titer of 3β,20S-Di-O-Glc-DM reached 2.6 g/L by fed-batch fermentation in a 3 L bioreactor. To our knowledge, this is the first report on demonstrating the anti-pancreatic cancer activity of F2 and 3β,20S-Di-O-Glc-DM, and achieving their de novo biosynthesis by the engineered yeasts. Our work presents an alternative approach to produce F2 and 3β,20S-Di-O-Glc-DM from renewable biomass, which lays a foundation for drug research and development. |
format | Online Article Text |
id | pubmed-9293705 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-92937052022-07-20 Metabolic engineering of yeasts for green and sustainable production of bioactive ginsenosides F2 and 3β,20S-Di-O-Glc-DM Jiang, Fenglin Zhou, Chen Li, Yan Deng, Haidong Gong, Ting Chen, Jingjing Chen, Tianjiao Yang, Jinling Zhu, Ping Acta Pharm Sin B Original Article Both natural ginsenoside F2 and unnatural ginsenoside 3β,20S-Di-O-Glc-DM were reported to exhibit anti-tumor activity. Traditional approaches for producing them rely on direct extraction from Panax ginseng, enzymatic catalysis or chemical synthesis, all of which result in low yield and high cost. Metabolic engineering of microbes has been recognized as a green and sustainable biotechnology to produce natural and unnatural products. Hence we engineered the complete biosynthetic pathways of F2 and 3β,20S-Di-O-Glc-DM in Saccharomyces cerevisiae via the CRISPR/Cas9 system. The titers of F2 and 3β,20S-Di-O-Glc-DM were increased from 1.2 to 21.0 mg/L and from 82.0 to 346.1 mg/L at shake flask level, respectively, by multistep metabolic engineering strategies. Additionally, pharmacological evaluation showed that both F2 and 3β,20S-Di-O-Glc-DM exhibited anti-pancreatic cancer activity and the activity of 3β,20S-Di-O-Glc-DM was even better. Furthermore, the titer of 3β,20S-Di-O-Glc-DM reached 2.6 g/L by fed-batch fermentation in a 3 L bioreactor. To our knowledge, this is the first report on demonstrating the anti-pancreatic cancer activity of F2 and 3β,20S-Di-O-Glc-DM, and achieving their de novo biosynthesis by the engineered yeasts. Our work presents an alternative approach to produce F2 and 3β,20S-Di-O-Glc-DM from renewable biomass, which lays a foundation for drug research and development. Elsevier 2022-07 2022-04-27 /pmc/articles/PMC9293705/ /pubmed/35865098 http://dx.doi.org/10.1016/j.apsb.2022.04.012 Text en © 2022 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Original Article Jiang, Fenglin Zhou, Chen Li, Yan Deng, Haidong Gong, Ting Chen, Jingjing Chen, Tianjiao Yang, Jinling Zhu, Ping Metabolic engineering of yeasts for green and sustainable production of bioactive ginsenosides F2 and 3β,20S-Di-O-Glc-DM |
title | Metabolic engineering of yeasts for green and sustainable production of bioactive ginsenosides F2 and 3β,20S-Di-O-Glc-DM |
title_full | Metabolic engineering of yeasts for green and sustainable production of bioactive ginsenosides F2 and 3β,20S-Di-O-Glc-DM |
title_fullStr | Metabolic engineering of yeasts for green and sustainable production of bioactive ginsenosides F2 and 3β,20S-Di-O-Glc-DM |
title_full_unstemmed | Metabolic engineering of yeasts for green and sustainable production of bioactive ginsenosides F2 and 3β,20S-Di-O-Glc-DM |
title_short | Metabolic engineering of yeasts for green and sustainable production of bioactive ginsenosides F2 and 3β,20S-Di-O-Glc-DM |
title_sort | metabolic engineering of yeasts for green and sustainable production of bioactive ginsenosides f2 and 3β,20s-di-o-glc-dm |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293705/ https://www.ncbi.nlm.nih.gov/pubmed/35865098 http://dx.doi.org/10.1016/j.apsb.2022.04.012 |
work_keys_str_mv | AT jiangfenglin metabolicengineeringofyeastsforgreenandsustainableproductionofbioactiveginsenosidesf2and3b20sdioglcdm AT zhouchen metabolicengineeringofyeastsforgreenandsustainableproductionofbioactiveginsenosidesf2and3b20sdioglcdm AT liyan metabolicengineeringofyeastsforgreenandsustainableproductionofbioactiveginsenosidesf2and3b20sdioglcdm AT denghaidong metabolicengineeringofyeastsforgreenandsustainableproductionofbioactiveginsenosidesf2and3b20sdioglcdm AT gongting metabolicengineeringofyeastsforgreenandsustainableproductionofbioactiveginsenosidesf2and3b20sdioglcdm AT chenjingjing metabolicengineeringofyeastsforgreenandsustainableproductionofbioactiveginsenosidesf2and3b20sdioglcdm AT chentianjiao metabolicengineeringofyeastsforgreenandsustainableproductionofbioactiveginsenosidesf2and3b20sdioglcdm AT yangjinling metabolicengineeringofyeastsforgreenandsustainableproductionofbioactiveginsenosidesf2and3b20sdioglcdm AT zhuping metabolicengineeringofyeastsforgreenandsustainableproductionofbioactiveginsenosidesf2and3b20sdioglcdm |